Author:
Garnier-Crussard Antoine,Krolak-Salmon Pierre
Reference34 articles.
1. Revisiting the cholinergic hypothesis in Alzheimer's disease: emerging evidence from translational and clinical research;Hampel;J Prev Alzheimers Dis,2019
2. Synthèse d’avis de la commission de transparence. ARICEPT (donépézil), EXELON (rivastigmine), REMINYL (galantamine), anticholinestérasiques EBIXA (mémantine), antagoniste non compétitif des récepteurs NMDA;Haute Autorité de santé,2016
3. Removal of drugs for Alzheimer's disease from the list of reimbursable drugs in France: analysis of change in drug use, disease management and cognition using the National Alzheimer Data Bank (BNA);Herr;Drugs Aging,2021
4. Evolution in the dispensation of drugs for Alzheimer's disease after removal from the list of reimbursable drugs in France;Noël;J Am Geriatr Soc,2021
5. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline;Raina;Ann Intern Med,2008